GlassScriptPhysician profile
Andrew D Mcleod
NPI 1275735888
$5,932.92
in general payments reported to CMS, 2019-2025
18 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $37.21 · 2021: $244 · 2022: $282 · 2023: $311 · 2024: $2,276 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,061 · Travel and Lodging: $841 · Consulting Fee: $750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,061.49 |
| Travel and Lodging | $841.10 |
| Consulting Fee | $750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $187.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,691.38 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $1,465.54 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $383.24 | 2023-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $324.90 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $319.06 | 2019-2025 | Clareon, Tryptyr, Eysuvis |
| Glaukos Corporation | $295.00 | 2024-2025 | Ce-Marked Kxla System, Istent Infinite |
| Dompe US, INC. | $271.71 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $243.01 | 2022-2023 | Tyrvaya |
| Coopervision INC. | $215.59 | 2019-2023 | Myday Contact Lens |
| Sight Sciences, INC. | $185.81 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $183.55 | 2021-2022 | |
| Rxsight INC | $82.73 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Sun Pharmaceutical Industries INC. | $77.77 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $68.95 | 2023-2024 | Lipiflow System Activator II (Disposable |
| Abbvie INC. | $54.12 | 2023-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.02 | 2020-2021 | |
| Lombart Brothers, INC. | $21.09 | 2025 | Opd-III |
| Abb Con-Cise Optical Group LLC | $18.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mcleod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.